ERBB2 and breast cancer: High PSMD3 expression showed poor Overall survival (OS), Relapse-free survival (RFS), and progression-free survival (PFS) in BC and poor OS and distant metastasis-free survival (DMFS) in HER2+/BC compared with low PSMD3 expression (Figure 6E), which is consistent with our results.